Details for Patent: 4,390,531

Summary for Patent: 4,390,531

Title:	Method of contraception using peak progestogen dosage
Abstract:	A method of contraception and a pharmaceutical package for effecting the method are disclosed. The method comprises a three phase sequence of estrogen/progestogen administration which is a daily sequence of unit dosages over a repeating cycle, which dosage sequence comprises, for one cycle: (a) administering, as phase one, about 20-40 .mu.g of ethinyl estradiol, (or of other estrogen in an amount sufficient to result in an equivalent effect) and about 0.3-0.8 mg of norethindrone (or of other progestogen in an amount sufficient to result in an equivalent effect) each day for 5-8 days, followed by; (b) administering, as phase two, the same dosage of estrogen and twice the dosage of progestogen each day as was administered each day in phase one, for 7-11 days, followed by; (c) administering, as phase three, the same dosage of estrogen and the same dosage of progestogen each day as was administered each day in phase one, for 3-7 days, followed by; (d) administering, as phase four, no therapeutically active dosage, i.e. either no treatment or a placebo each day for 6-8 days, with the proviso that the total number of days in phases one through three is 21.
Inventor(s):	Edgren; Richard A. (Woodside, CA)
Assignee:	Syntex Pharmaceuticals International Ltd. (Hamilton, BM)
Application Number:	06/291,533
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 4,390,531

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,390,531

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	560922
Australia	8697682
Canada	1198057
Germany	3229612
United Kingdom	2104779